Circulating Tumor DNA Predicts the Response and Prognosis in Patients With Early Breast Cancer Receiving Neoadjuvant Chemotherapy

PURPOSE: Many patients with breast cancer still relapse after curative treatment. How to identify the ones with high relapse risk remains a critical problem. Circulating tumor DNA (ctDNA) has recently become a promising marker to monitor tumor burden. Whether ctDNA can be used to predict the respons...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JCO Precis Oncol
Autors principals: Li, Shunying, Lai, Hongna, Liu, Jieqiong, Liu, Yujie, Jin, Liang, Li, Yudong, Liu, Fengtao, Gong, Yuhua, Guan, Yanfang, Yi, Xin, Shi, Qianfeng, Cai, Zijie, Li, Qian, Li, Ying, Zhu, Mengdi, Wang, Jingru, Yang, Yaping, Wei, Wei, Yin, Dong, Song, Erwei, Liu, Qiang
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2020
Matèries:
Original Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7450928/
https://ncbi.nlm.nih.gov/pubmed/32923909
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.19.00292
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars